Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Cogstate Ltd ( (AU:CGS) ) has provided an announcement.
Cogstate Ltd announced the retirement of Mr. Richard van den Broek as a non-executive director, who has been with the company since 2010 and was its first USA-based non-executive director. Mr. van den Broek, a former healthcare analyst and experienced investor in the pharma/biotech market, has significantly contributed to the company through his knowledge of drug development pipelines and industry trends. His departure comes at a time when Cogstate is experiencing exciting technological advancements in cognitive measurement, and he will remain a shareholder and advisor to the company.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$1.80 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
More about Cogstate Ltd
Cogstate Ltd is a neuroscience technology company that focuses on optimizing brain health assessments to advance the development of new medicines and enable earlier clinical insights in healthcare. The company provides rapid, reliable, and highly sensitive computerized cognitive tests and supports electronic clinical outcome assessment solutions. Cogstate collaborates with biopharmaceutical companies, academic institutions, and healthcare providers to offer digital measures of cognition, with partnerships including pharmaceutical company Eisai for distribution in the USA and Asia.
Average Trading Volume: 126,100
Technical Sentiment Signal: Buy
Current Market Cap: A$228.7M
See more data about CGS stock on TipRanks’ Stock Analysis page.